ASX - Delayed Quote AUD

Orthocell Limited (OCC.AX)

Compare
1.4050
-0.0300
(-2.09%)
At close: 4:10:37 PM GMT+11
Loading Chart for OCC.AX
  • Previous Close 1.4350
  • Open 1.5000
  • Bid 1.4050 x --
  • Ask 1.4100 x --
  • Day's Range 1.3500 - 1.5800
  • 52 Week Range 0.3500 - 1.7900
  • Volume 4,881,444
  • Avg. Volume 1,589,246
  • Market Cap (intraday) 347.236M
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date Feb 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

orthocell.com

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: OCC.AX

View More

Performance Overview: OCC.AX

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

OCC.AX
3.69%
S&P/ASX 200 [XJO] (^AXJO)
6.02%

1-Year Return

OCC.AX
238.55%
S&P/ASX 200 [XJO] (^AXJO)
1.36%

3-Year Return

OCC.AX
234.52%
S&P/ASX 200 [XJO] (^AXJO)
2.05%

5-Year Return

OCC.AX
353.23%
S&P/ASX 200 [XJO] (^AXJO)
51.31%

Compare To: OCC.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OCC.AX

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    339.98M

  • Enterprise Value

    309.79M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    46.59

  • Price/Book (mrq)

    17.31

  • Enterprise Value/Revenue

    48.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -51.42%

  • Return on Assets (ttm)

    -20.32%

  • Return on Equity (ttm)

    -29.76%

  • Revenue (ttm)

    6.31M

  • Net Income Avi to Common (ttm)

    -3.25M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    30.84M

  • Total Debt/Equity (mrq)

    3.35%

  • Levered Free Cash Flow (ttm)

    -8.59M

Research Analysis: OCC.AX

View More

Company Insights: OCC.AX

Research Reports: OCC.AX

View More

People Also Watch